Novavax, Inc. reaffirmed revenue guidance for the full year 2022. For the period, the company reaffirms total revenue guidance of approximately $2 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.92 USD | +0.77% | -8.97% | -18.83% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.83% | 544M | |
-2.16% | 41.35B | |
+42.15% | 40.38B | |
+1.78% | 39.05B | |
-14.19% | 26.67B | |
+1.61% | 24.07B | |
-24.55% | 18.36B | |
-3.94% | 11.68B | |
+20.86% | 11.6B | |
+7.47% | 11.15B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022